Dr Huseyin Dogan and Dr Paul Whittington have organised an Assistive Technology Symposium on Monday 24th June 2019 in Share Lecture Theatre, Fusion Building, Talbot Campus, Bournemouth University, 09:00 – 17:00.
The 2nd Assistive Technology Symposium at Bournemouth University will be a fusion of research domains: Digital Health, Educational Technologies, Human Computer Interaction, Inclusion, Learning Strategies through Metacognition, Smart Technologies, and User Experience. Download Assistive Technology Symposium 2019 Programme.
We have presentations from a range of speakers including academics, researchers and postgraduate students, including a keynote presentation from Steve Tyler, Assistive Technology Director of Leonard Cheshire. The Symposium will conclude with a Panel discussing collaborative projects and future Assistive Technology research.
There is no cost to attend the event, but delegates are required to register online through Eventbrite at:
Registration includes refreshments and a finger buffet lunch (please advise by email of any dietary requirements). Tickets will be available on a first come first served basis and there is a maximum capacity of 60 delegates.
If you have any questions regarding the event, please do not hesitate to contact Dr Paul Whittington by email: whittingtonp@bournemouth.ac.uk
Assistive Technology Symposium 2019
Recent Assistive Technology Public Engagement Events
BBC South filming of Assistive Technology research










BU academic publishes in online newspaper in Nepal
Final day of the ESRC Festival of Social Science
Using Art to enhance Research
Register now to attend the 17th Annual Postgraduate Research Conference – Wednesday 3 December 2025
ECR Funding Open Call: Research Culture & Community Grant – Application Deadline Friday 12 December
MSCA Postdoctoral Fellowships 2025 Call
ERC Advanced Grant 2025 Webinar
Horizon Europe Work Programme 2025 Published
Horizon Europe 2025 Work Programme pre-Published
Update on UKRO services
European research project exploring use of ‘virtual twins’ to better manage metabolic associated fatty liver disease